The global hemophilia therapeutics market was valued at $6.5 billion in 2009. It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from $6.5 billion in 2009 to $10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.
Strong Pipeline Candidates are expected to Intensify Future Competition
The hemophilia therapeutics developmental pipeline is strong with about 31 molecules in various phases of clinical development. Most of the molecules in clinical development are first-in-class or me-too molecules. There are eight first-in-class molecules which are in the discovery and preclinical phase. These molecules include classes such as recombinant coagulation factor, thrombin generation, gene therapy, stem cell therapy and plasma-derived coagulation factor molecules.
GlobalData, the industry analysis specialist, has released its new report, “Hemophilia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.